Secretory phospholipase A2 in SARS-CoV-2 infection and multisystem inflammatory syndrome in children (MIS-C)
Authors:
Open Access
- 13 July 2021
- journal article
- research article
- Published by Frontiers Media SA in Experimental Biology and Medicine
- Vol. 246 (23) , 2543-2552
Abstract
Secretory phospholipase 2 (sPLA2) acts as a mediator between proximal and distal events of the inflammatory cascade. Its role in SARS-CoV-2 infection is unknown, but could contribute to COVID-19 inflammasome activation and cellular damage. We present the first report of plasma sPLA2 levels in adults and children with COVID-19 compared with controls. Currently asymptomatic adults with a history of recent COVID-19 infection (≥4 weeks before) identified by SARS-CoV-2 IgG antibodies had sPLA2 levels similar to those who were seronegative (9 ± 6 vs.17 ± 28 ng/mL, P = 0.26). In contrast, children hospitalized with severe COVID-19 had significantly elevated sPLA2 compared with those with mild or asymptomatic SARS-CoV-2 infection (269 ± 137 vs. 2 ± 3 ng/mL, P = 0.01). Among children hospitalized with multisystem inflammatory syndrome in children (MIS-C), all had severe disease requiring pediatric intensive care unit (PICU) admission. sPLA2 levels were significantly higher in those with acute illness P = 0.04). Thus, sPLA2 levels correlated with COVID-19 severity and acute MIS-C in children, implicating a role in inflammasome activation and disease pathogenesis. sPLA2 may be a useful biomarker to stratify risk and guide patient management for children with acute COVID-19 and MIS-C. Therapeutic compounds targeting sPLA2 and inflammasome activation warrant consideration.Keywords
Funding Information
- The Children's Healthcare of Atlanta and Emory University's Children’s Clinical and Translational Discovery Core.
- The Woodruff Health Sciences Center Synergy Award
- Michael and Natalia Beinenson
- The Wilbur and Hilda Glenn Family Foundation
- The Scott Hudgens Family Foundation
- Emory COVID-19 CURE award
This publication has 77 references indexed in Scilit:
- Secretory phospholipase A2 pathway in various types of lung injury in neonates and infants: a multicentre translational studyBMC Pediatrics, 2011
- Secretory phospholipase A2: a marker of infection in febrile children presenting to a pediatric EDThe American Journal of Emergency Medicine, 2011
- Diannexin Protects against Renal Ischemia Reperfusion Injury and Targets Phosphatidylserines in Ischemic TissuePLOS ONE, 2011
- Diannexin Decreases Inflammatory Cell Infiltration Into the Islet Graft, Reduces β-Cell Apoptosis, and Improves Early Graft FunctionTransplantation, 2010
- Diannexin Reduces No-Reflow after Reperfusion in Rabbits with Large Ischemic Myocardial Risk ZonesCardiovascular Therapeutics, 2010
- Cross-Talk between Oxysterols and Glucocorticoids: Differential Regulation of Secreted Phopholipase A2 and Impact on Oligodendrocyte DeathPLOS ONE, 2009
- Newcastle disease virus-induced cytopathic effect in infected cells is caused by apoptosisVirus Research, 2009
- Varespladib (A-002), a Secretory Phospholipase A2 Inhibitor, Reduces Atherosclerosis and Aneurysm Formation in ApoE− / − MiceJournal of Cardiovascular Pharmacology, 2009
- Transfusion prevents acute chest syndrome predicted by elevated secretory phospholipase A2British Journal of Haematology, 2006
- Secretory Phospholipase A2Levels in Patients with Sickle Cell Disease and Acute Chest SyndromeHemoglobin, 2006